本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Viking Therapeutics, Inc.

27.56
-1.6553-5.66%
成交量:98.09萬
成交額:2,733.17萬
市值:35.28億
市盈率:-5.09
高:28.58
開:28.46
低:27.42
收:29.22
52周最高:43.10
52周最低:23.82
股本:1.28億
流通股本:1.24億
量比:0.68
換手率:0.79%
股息:- -
股息率:- -
每股收益(TTM):-5.4200
每股收益(LYR):-3.1920
淨資產收益率:-96.37%
總資產收益率:-47.23%
市淨率:5.99
市盈率(LYR):-8.64

資料載入中...

2025/02/05

重要事件披露

Form 8-K - Current report
2025/01/06

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/01/06

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/01/06

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/11/15

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/08

關聯方擬減持公告

Form 144 | VIKING THERAPEUTICS, INC. 董事 Lawson Macartney 擬減持2000股,總價約13.73萬美元
2024/11/04

重要事件披露

Form 8-K - Current report
2024/10/28

關聯方擬減持公告

Form 144 | Viking Therapeutics高管Greg Zante擬減持131687股,總價約1028萬美元
2024/10/25

關聯方擬減持公告

Form 144 | Viking Therapeutics董事 Rouan Sarah Kathryn 擬減持11000股,總價約88.94萬美元
2024/10/25

關聯方擬減持公告

Form 144 | Viking Therapeutics董事 Singleton擬減持16000股,總價約127萬美元
2024/10/23

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/10/23

重要事件披露

Form 8-K - Current report
2024/10/18

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/09/20

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/09/20

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/21

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/21

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/19

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/19

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/14

關聯方擬減持公告

Form 144 - Report of proposed sale of securities